The Flavagline Compound 1-(2-(dimethylamino)acetyl)-Rocaglaol Induces Apoptosis in K562 Cells by Regulating the PI3K/Akt/mTOR, JAK2/STAT3, and MAPK Pathways

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2022 Aug 12

PMID 35959422

Authors

Xinmei Yang

Xijun Wu

Xiaosen Wu

Lei Huang

Jingrui Song

Chunmao Yuan

Zhixu He

Yanmei Li

Affiliations

Soon will be listed here.

Abstract

Purpose: Chronic myelogenous leukemia (CML) is a hematological malignancy with increased proliferation of cells of the myeloid series. This can disrupt normal hematopoiesis. The 1-(2-(dimethylamino)acetyl)-rocaglaol (MQ-16) is a new synthetic flavagline compound that showed promising activity in chronic myeloid leukemia K562 cells. This study aims to analyze the underlying mechanisms of MQ-16 against CML.

Methods: Growth, cell cycle progression, and apoptosis were assessed in K562 cells following MQ-16 exposure by MTT assay and flow cytometry. The effect of MQ-16 on DNA strands between nucleosomes was examined by 1% agarose gel electrophoresis. PI3K/Akt/mTOR, JAK2/STAT3, and mitogen-activated protein kinase (MAPK) pathway-related proteins were detected in MQ-16-treated K562 cells by Western blot.

Results: MQ-16 significantly inhibited the proliferation of K562 cells and arrested the cell cycle at the G2/M phase in a time- and concentration-dependent manner. MQ-16 induced mitochondria-dependent apoptosis by downregulating the anti-apoptotic proteins Bcl-2 and Bcl-xL and induced time- and concentration-dependent DNA fragmentation. In addition, MQ-16 affected the expression of PI3K/Akt/mTOR, JAK2/STAT3, and MAPK pathway-related proteins.

Conclusion: In summary, MQ-16 appears to be a promising chemotherapeutic drug for treating CML.

Citing Articles

LILRB4 knockdown inhibits aortic dissection development by regulating pyroptosis and the JAK2/STAT3 signaling pathway.

Xiong J, Ling J, Yan J, Duan Y, Yu J, Li W Sci Rep. 2024; 14(1):15564.

PMID: 38971897 PMC: 11227527. DOI: 10.1038/s41598-024-66482-3.

Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis.

Liu X, Hai Y, Dong J, Xu L, Hou W, Su J Int J Oncol. 2022; 61(6).

PMID: 36321791 PMC: 9635866. DOI: 10.3892/ijo.2022.5447.

References

Pilati C, Zucman-Rossi J . Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. Cytokine Growth Factor Rev. 2015; 26(5):499-506. DOI: 10.1016/j.cytogfr.2015.07.010. View

Song J, Yuan C, Yang J, Liu T, Yao Y, Xiao X . Novel flavagline-like compounds with potent Fli-1 inhibitory activity suppress diverse types of leukemia. FEBS J. 2018; 285(24):4631-4645. DOI: 10.1111/febs.14690. View

Xia Z, Dickens M, Raingeaud J, Davis R, Greenberg M . Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995; 270(5240):1326-31. DOI: 10.1126/science.270.5240.1326. View

Thornberry N, Lazebnik Y . Caspases: enemies within. Science. 1998; 281(5381):1312-6. DOI: 10.1126/science.281.5381.1312. View

Singh R, Letai A, Sarosiek K . Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019; 20(3):175-193. PMC: 7325303. DOI: 10.1038/s41580-018-0089-8. View

Fresno Vara J, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M . PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004; 30(2):193-204. DOI: 10.1016/j.ctrv.2003.07.007. View

Steelman L, Abrams S, Whelan J, Bertrand F, Ludwig D, Basecke J . Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia. 2008; 22(4):686-707. DOI: 10.1038/leu.2008.26. View

Burgers L, Furst R . Natural products as drugs and tools for influencing core processes of eukaryotic mRNA translation. Pharmacol Res. 2021; 170:105535. DOI: 10.1016/j.phrs.2021.105535. View

Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B . The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019; 698:120-128. DOI: 10.1016/j.gene.2019.02.076. View

10.

Juliusson G, Hough R . Leukemia. Prog Tumor Res. 2016; 43:87-100. DOI: 10.1159/000447076. View

11.

Vachhani P, Bose P, Rahmani M, Grant S . Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. Physiol Genomics. 2014; 46(13):448-56. PMC: 4080281. DOI: 10.1152/physiolgenomics.00173.2013. View

12.

Hochhaus A, Baccarani M, Silver R, Schiffer C, Apperley J, Cervantes F . European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984. PMC: 7214240. DOI: 10.1038/s41375-020-0776-2. View

13.

Ebada S, Lajkiewicz N, Porco Jr J, Li-Weber M, Proksch P . Chemistry and biology of rocaglamides (= flavaglines) and related derivatives from aglaia species (meliaceae). Prog Chem Org Nat Prod. 2011; 94:1-58. PMC: 4157394. DOI: 10.1007/978-3-7091-0748-5_1. View

14.

Chen X, Song J, Yuan D, Rao Q, Jiang K, Feng S . Incaspitolide A extracted from Carpesium cernuum induces apoptosis in vitro via the PI3K/AKT pathway in benign prostatic hyperplasia. Biosci Rep. 2021; 41(6). PMC: 8220449. DOI: 10.1042/BSR20210477. View

15.

Roos W, Kaina B . DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2012; 332(2):237-48. DOI: 10.1016/j.canlet.2012.01.007. View

16.

Carneiro B, El-Deiry W . Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020; 17(7):395-417. PMC: 8211386. DOI: 10.1038/s41571-020-0341-y. View

17.

Callahan K, Minhajuddin M, Corbett C, Lagadinou E, Rossi R, Grose V . Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. Leukemia. 2014; 28(10):1960-8. PMC: 4148474. DOI: 10.1038/leu.2014.93. View

18.

Roos W, Kaina B . DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006; 12(9):440-50. DOI: 10.1016/j.molmed.2006.07.007. View

19.

Jain P, Kantarjian H, Ghorab A, Sasaki K, Jabbour E, Gonzalez G . Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017; 123(22):4391-4402. PMC: 5673547. DOI: 10.1002/cncr.30864. View

20.

Hausott B, Greger H, Marian B . Flavaglines: a group of efficient growth inhibitors block cell cycle progression and induce apoptosis in colorectal cancer cells. Int J Cancer. 2004; 109(6):933-40. DOI: 10.1002/ijc.20033. View